RJA
INO icon

Raymond James & Associates’s Inovio Pharmaceuticals INO Stock Holding History

Raymond James & Associates’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-873
Closed -$5.34K – 3977
2023
Q4 		$5.34K Sell
873
-417
-32% -$2.06K ﹤0.01% 3815
2023
Q3 		$6.02K Buy
1,290
+17
+1% +$94 ﹤0.01% 3775
2023
Q2 		$6.82K Sell
1,273
-66
-5% -$532 ﹤0.01% 3821
2023
Q1 		$13.2K Buy
1,339
+64
+5% +$1.09K ﹤0.01% 3822
2022
Q4 		$23.9K Sell
1,275
-321
-20% -$7.28K ﹤0.01% 3778
2022
Q3 		$33K Sell
1,596
-785
-33% -$20.1K ﹤0.01% 3747
2022
Q2 		$49K Buy
2,381
+8
+0.3% +$225 ﹤0.01% 3789
2022
Q1 		$102K Sell
2,373
-222
-9% -$10K ﹤0.01% 3819
2021
Q4 		$155K Sell
2,595
-65
-2% -$5.21K ﹤0.01% 3770
2021
Q3 		$229K Buy
2,660
+775
+41% +$77.8K ﹤0.01% 3589
2021
Q2 		$210K Sell
1,885
-92
-5% -$8.84K ﹤0.01% 3657
2021
Q1 		$220K Sell
1,977
-553
-22% -$72.7K ﹤0.01% 3551
2020
Q4 		$269K Buy
2,530
+19
+0.8% +$2.53K ﹤0.01% 3185
2020
Q3 		$350K Buy
2,511
+459
+22% +$95.7K ﹤0.01% 2856
2020
Q2 		$664K Buy
2,052
+205
+11% +$32.9K ﹤0.01% 2419
2020
Q1 		$165K Hold
1,847
– – ﹤0.01% 3099
2019
Q4 		$73K Buy
1,847
+340
+23% +$10.2K ﹤0.01% 3513
2019
Q3 		$37K Buy
1,507
+209
+16% +$6.36K ﹤0.01% 3497
2019
Q2 		$46K Hold
1,298
– – ﹤0.01% 3508
2019
Q1 		$58K Sell
1,298
-818
-39% -$41.2K ﹤0.01% 3465
2018
Q4 		$102K Buy
2,116
+1,165
+123% +$70.8K ﹤0.01% 3299
2018
Q3 		$63K Buy
+951
New +$53K ﹤0.01% 3478
2017
Q2 		– Sell
-843
Closed -$67K – 3382
2017
Q1 		$67K Sell
843
-33
-4% -$2.63K ﹤0.01% 3118
2016
Q4 		$73K Sell
876
-183
-17% -$16.5K ﹤0.01% 3062
2016
Q3 		$118K Buy
1,059
+116
+12% +$12.8K ﹤0.01% 2968
2016
Q2 		$105K Buy
943
+85
+10% +$10.3K ﹤0.01% 2793
2016
Q1 		$90K Buy
+858
New +$66.2K ﹤0.01% 2733

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Raymond James & Associates's INO Position: Q1 2024 in Review

Raymond James & Associates sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 873 shares — an estimated $5.34K sold.

Raymond James & Associates first reported a position in INO in Q1 2016 and held it in 27 quarters. The position peaked at $664K in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Raymond James & Associates reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 873 Inovio Pharmaceuticals shares in Q1 2024, an estimated $5.34K.
  • Raymond James & Associates first reported a position in Inovio Pharmaceuticals in Q1 2016 and held it in 27 quarters.
  • Raymond James & Associates's Inovio Pharmaceuticals position peaked at $664K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.